


PATENT

<b>CERTIFICATE OF DELIVERY VIA FACSIMILE</b>	
I hereby certify that this paper is being delivered via Facsimile to the U.S. Patent Office in accordance with 37 CFR § 1.6(d), addressed to the Commissioner for Patents, Alexandria, VA 22313-1450, on the date indicated:	
 _____ Name	<u>Nov 10/05</u> _____ Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**RECEIVED  
CENTRAL FAX CENTER**

NOV 10 2005

In the application of: Thomas R. Cech, *et al.*

Serial No.: 10/044,692

Filing Date: January 11, 2002

Attorney Docket: 015389-002640US; 018/213C

For: NUCLEIC ACID VACCINE FOR ELICITING AN  
IMMUNE RESPONSE AGAINST TELOMERASE  
REVERSE TRANSCRIPTASE

Art Unit: 1642

Examiner: Susan Nmn Unger

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Arlington, VA 22313-1450

Dear Sir:

The information listed in the accompanying form PTO-1449 and provided herewith may be material to examination of this application and is submitted in compliance with the duty of disclosure under 37 CFR § 1.56.


The Examiner is requested to make this information of record in the application.

PATENT  
Serial No. 10/044,692  
Docket: 015389-002640US; 018/213C

This Information Disclosure Statement is not to be construed as a representation that a full search for relevant information has been made, that all relevant information has been found, or that the information provided with this Statement is considered to be material to patentability of the claimed invention as defined under 37 CFR § 1.56(b).

This Information Disclosure Statement is being filed before the mailing of a final Action, Notice of Allowance or an Action that closes prosecution, and is accompanied by the fee set forth in 37 CFR § 1.17(p).

Respectfully submitted,

  
J. Michael Schiff  
Registration No. 40,253

GERON CORPORATION  
230 Constitution Drive  
Menlo Park, CA 94025  
Telephone: (650) 473-7715  
Fax: (650) 473-8654

November 10, 2005

<b>Form 1449 (modified)</b> <b>Supplemental</b> <b>Information Disclosure</b> <b>Statement By Applicant</b>  (Use Several Sheets if Necessary)	<b>Docket:</b> 015389-002640US; 018/213C <b>U.S.S.N.:</b> 10/044,692
	<b>Title:</b> Nucleic Acid Vaccine for Eliciting an Immune Response Against Telomerase Reverse Transcriptase <b>Inventors:</b> Thomas R. Cech, et al.
	<b>Filing Date:</b> January 11, 2002 <b>Group:</b> 1642

## U.S. Patent Documents

Examiner Initial	Ref.	Document No.	Publication Date	Inventor	Title
	FA	6,093,809	07/25/00	Cech, T. R., et al.	Telomerase
	FB	6,166,178	12/26/00	Cech, T. R., et al.	Telomerase Catalytic Subunit
	FC	6,261,836	07/17/01	Cech, T. R., et al.	Telomerase
	FD	6,309,867	10/30/01	Cech, T. R., et al.	Novel Telomerase
	FE	6,337,200	01/08/02	Morin, G. B.	Human Telomerase Catalytic Subunit Variants
	FF	6,440,735	08/27/02	Gaeta, F.C.A.	Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer
	FG	6,444,650	09/03/02	Cech, T. R., et al.	Antisense Compositions for Detecting and Inhibiting Telomerase Reverse Transcriptase
	FH	6,475,789	11/05/02	Cech, T. R., et al.	Human Telomerase Catalytic Subunit: Diagnostic and Therapeutic Methods
	FI	6,517,834	02/11/03	Weinrich, S.L., et al.	Purified Telomerase
	FJ	6,545,133	04/08/03	Weinrich, S.L., et al.	A Method for Purifying Telomerase
	FK	6,610,839	08/26/03	Morin, G. B., et al.	Promoter for Telomerase Reverse Transcriptase
	FL	6,617,110	09/09/03	Cech, T. R., et al.	Cells Immortalized With Telomerase Reverse Transcriptase for Use in Drug Screening
	FM	6,627,619	09/30/03	Cech, T. R., et al.	Antisense Compositions for Detecting and Inhibiting Telomerase Reverse Transcriptase
	FN	6,767,719	07/27/04	Morin, G. B., et al.	Mouse Telomerase Reverse Transcriptase
	FO	6,787,133	07/09/04	Weinrich, S.L., et al.	Using Purified Telomerase to Identify Telomerase Activators and Inhibitors
	FP	6,777,203	08/17/04	Morin, G. B., et al.	Telomerase Promoter Driving Expression of Therapeutic Gene Sequences
	FQ	6,808,880	10/26/04	Cech, T. R., et al.	Method for Detecting Polynucleotides Encoding Telomerase
	FR	6,921,664	07/26/05	Cech, T. R., et al.	Telomerase
	FS	6,927,285	08/09/05	Cech, T. R., et al.	Genes for Human Telomerase Reverse Transcriptase and Telomerase Variants
	FT	US-2002-0164786-A1	11/07/02	Cech, T. R., et al.	Telomerase Peptides and Immunogenic Compositions
	FU	US-2003-0059787-A1	03/27/03	Cech, T. R., et al.	Methods for Detecting Nucleic Acids Encoding Human Telomerase Reverse Transcriptase
	FV	US-2003-0100093-A1	05/29/03	Cech, T. R., et al.	Mammalian Cells that have Increased Proliferative Capacity

Examiner	Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
 PTO-1449 — Page 1

<b>Form 1449 (modified)</b> Supplemental Information Disclosure Statement By Applicant (Use Several Sheets If Necessary)	<b>Docket:</b> 015389-002640US; 018/213C	<b>U.S.S.N.:</b> 10/044,692
	<b>Title:</b> Nucleic Acid Vaccine for Eliciting an Immune Response Against Telomerase Reverse Transcriptase	
	<b>Inventors:</b> Thomas R. Cech, et al.	
	<b>Filing Date:</b> January 11, 2002	<b>Group:</b> 1642

**Foreign Patent or Published Foreign Patent Application**

Examiner Initial	Ref.	Document No.	Publication Date	Title	Translation
None					

**Other Documents**

Examiner Initial	Ref.	Author, Title, Source, Date
	FW	USSN 09/432,503, Pending Claims, Cech, T. R., et al., Increasing the Proliferative Capacity of Cells Using Telomerase Reverse Transcriptase
	FX	USSN 09/721,506, Pending Claims, Cech, T. R., et al., Nucleic Acids Encoding Human Telomerase Reverse Transcriptase and Related Homologs Having Telomerase Activity
	FY	USSN 09/843,676, Allowed Claims, Cech, T. R., et al., Telomerase Peptides and Immunogenic Compositions
	FZA	USSN 10/054,611, Allowed Claims, Cech, T. R., et al., Methods for Detecting Nucleic Acids Encoding Human Telomerase Reverse Transcriptase
	FZB	USSN 10/044,539, Pending Claims, Cech, T. R., et al., Mammalian Cells that have Increased Proliferative Capacity

Examiner	Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
 PTO-1449 — Page 2